PARP rivals close in on AZ and Merck's market leading Lynparza - - Pharmaphorum

Retrieved on: 2022-10-04 18:29:25

Tags for this article:

Click the tags to see associated articles and topics

PARP rivals close in on AZ and Merck's market leading Lynparza - - Pharmaphorum. View article details on hiswai:

Excerpt

AZ and Merck's drug was also approved as a second-line therapy after Xtandi or Pfizer's Zytiga (abiraterone) for mCRPC in 2020, but only as a ...

Article found on: pharmaphorum.com